Tracy T Smith1, Matthew B Schaff2, Laura E Rupprecht2, Rachel L Schassburger2, Deanne M Buffalari2, Sharon E Murphy3, Alan F Sved4, Eric C Donny5. 1. Department of Psychology, University of Pittsburgh, United States. 2. Department of Neuroscience, University of Pittsburgh, United States. 3. College of Biological Sciences, University of Minnesota, United States. 4. Department of Psychology, University of Pittsburgh, United States; Department of Neuroscience, University of Pittsburgh, United States. 5. Department of Psychology, University of Pittsburgh, United States. Electronic address: edonny@pitt.edu.
Abstract
INTRODUCTION: Although nicotine is the primary reinforcing constituent in cigarettes, there is evidence that other constituents in cigarette smoke may interact with nicotine to reinforce smoking behavior. METHODS: The present experiments investigated whether a novel combination of these cigarette smoke constituents would increase nicotine self-administration in adult male rats. The constituents included five minor alkaloids (anabasine, nornicotine, cotinine, myosmine, and anatabine), two β-carbolines (harman and norharman), and acetaldehyde. All doses were indexed to be proportional to concentrations in cigarette smoke given a standard dose of nicotine used in rodent self-administration, or ten times higher than this standard. To model MAO inhibition seen in chronic smokers, some groups received separate injections of tranylcypromine prior to each self-administration session. RESULTS: Tranylcypromine increased low-dose nicotine self-administration independent of other smoke constituents, which had no effect on self-administration behavior. The effect of tranylcypromine was confirmed across a large range of reinforcement schedules. The effect of tranylcypromine on low-dose nicotine self-administration was observed regardless of whether the injection was delivered 1-h or 23-h prior to the self-administration session, consistent with the interpretation that MAO inhibition was responsible for the increase in self-administration, instead of acute off-target effects. CONCLUSIONS: These data suggest that this cocktail of constituents does not significantly alter the primary reinforcing effects of nicotine, but constituents that inhibit MAO may increase the primary reinforcing effects of nicotine, especially at low doses.
INTRODUCTION: Although nicotine is the primary reinforcing constituent in cigarettes, there is evidence that other constituents in cigarette smoke may interact with nicotine to reinforce smoking behavior. METHODS: The present experiments investigated whether a novel combination of these cigarette smoke constituents would increase nicotine self-administration in adult male rats. The constituents included five minor alkaloids (anabasine, nornicotine, cotinine, myosmine, and anatabine), two β-carbolines (harman and norharman), and acetaldehyde. All doses were indexed to be proportional to concentrations in cigarette smoke given a standard dose of nicotine used in rodent self-administration, or ten times higher than this standard. To model MAO inhibition seen in chronic smokers, some groups received separate injections of tranylcypromine prior to each self-administration session. RESULTS:Tranylcypromine increased low-dose nicotine self-administration independent of other smoke constituents, which had no effect on self-administration behavior. The effect of tranylcypromine was confirmed across a large range of reinforcement schedules. The effect of tranylcypromine on low-dose nicotine self-administration was observed regardless of whether the injection was delivered 1-h or 23-h prior to the self-administration session, consistent with the interpretation that MAO inhibition was responsible for the increase in self-administration, instead of acute off-target effects. CONCLUSIONS: These data suggest that this cocktail of constituents does not significantly alter the primary reinforcing effects of nicotine, but constituents that inhibit MAO may increase the primary reinforcing effects of nicotine, especially at low doses.
Authors: Karine Guillem; Caroline Vouillac; Marc R Azar; Loren H Parsons; George F Koob; Martine Cador; Luis Stinus Journal: J Neurosci Date: 2005-09-21 Impact factor: 6.167
Authors: Eric C Donny; Nadia Chaudhri; Anthony R Caggiula; F Fay Evans-Martin; Sheri Booth; Maysa A Gharib; Laure A Clements; Alan F Sved Journal: Psychopharmacology (Berl) Date: 2003-05-28 Impact factor: 4.530
Authors: Yayi Swain; Peter Muelken; Mark G LeSage; Jonathan C Gewirtz; Andrew C Harris Journal: Pharmacol Biochem Behav Date: 2018-02-02 Impact factor: 3.533
Authors: Jack E Henningfield; Tracy T Smith; Bethea A Kleykamp; Reginald V Fant; Eric C Donny Journal: Psychopharmacology (Berl) Date: 2016-10-21 Impact factor: 4.530
Authors: Jason D Robinson; George Kypriotakis; Mustafa Al'absi; Rachel L Denlinger-Apte; David J Drobes; Scott J Leischow; F Joseph McClernon; Lauren R Pacek; Herbert H Severson; Tracy T Smith; Eric C Donny; Xianghua Luo; Joni A Jensen; Lori G Strayer; Paul M Cinciripini; Dorothy K Hatsukami Journal: Nicotine Tob Res Date: 2020-07-16 Impact factor: 4.244
Authors: Julie A Marusich; Mahesh Darna; A George Wilson; Emily D Denehy; Amanda Ebben; Agripina G Deaciuc; Linda P Dwoskin; Michael T Bardo; Timothy W Lefever; Jenny L Wiley; Chad J Reissig; Kia J Jackson Journal: Eur J Pharmacol Date: 2017-08-26 Impact factor: 4.432
Authors: Christie D Fowler; Cassandra D Gipson; Bethea A Kleykamp; Laura E Rupprecht; Paul T Harrell; Vaughan W Rees; Thomas J Gould; Jason Oliver; Deniz Bagdas; M Imad Damaj; Heath D Schmidt; Alexander Duncan; Mariella De Biasi Journal: Nicotine Tob Res Date: 2018-06-07 Impact factor: 4.244
Authors: Tracy T Smith; Laura E Rupprecht; Samantha N Cwalina; Matthew J Onimus; Sharon E Murphy; Eric C Donny; Alan F Sved Journal: Neuropsychopharmacology Date: 2016-03-09 Impact factor: 7.853